文献速递角膜与眼表疾病小儿眼科与斜弱视

儿童角膜交联:传统与加速治疗视觉及地形图结局比较

Pediatric Corneal Cross-linking: Comparison of Visual and Topographic Outcomes Between Conventional and Accelerated Treatment.
PubMed 文献 · Am J Ophthalmol · 2017-08-31

本研究为单中心回顾性连续病例系列,比较儿童圆锥角膜患者接受传统角膜交联(C-CXL,39眼)与加速角膜交联(A-CXL,39眼)后1年的视觉和地形图结局。两组在裸眼视力、最佳矫正视力和最大角膜曲率Kmax变化上均无显著差异,治疗失败率分别为23.1%和15.4%(P=0.389),不良事件仅C-CXL组1眼出现。作者结论认为加速方案与传统方案疗效相当。

要点

  • 儿童圆锥角膜C-CXL与A-CXL术后1年UCVA、BCVA和Kmax变化无显著差异。
  • 治疗失败率C-CXL组23.1%(9/39眼) vs A-CXL组15.4%(6/39眼),P=0.389。
  • 不良事件仅C-CXL组1眼出现,表现为BCVA较基线下降≥2行Snellen视力。

核心结论

  • 在这项回顾性比较中,加速方案治疗儿童圆锥角膜与传统方案同样有效。

研究设计与样本

  • 比较性、回顾性、连续病例系列,单中心分析58例患者78眼,C-CXL组39眼、A-CXL组39眼,随访12个月无失访。

主要发现

  • C-CXL组与A-CXL组术后12个月较术前UCVA变化为0.01 logMAR(95%CI -0.14至0.15,P=0.944),两组间无显著差异。
  • C-CXL组与A-CXL组术后12个月较术前BCVA变化为0.05 logMAR(95%CI -0.05至0.15,P=0.310),两组间无显著差异。
  • C-CXL组与A-CXL组术后12个月较术前Kmax变化为-0.77 D(95%CI -2.20至0.65,P=0.282),两组间无显著差异。
  • 治疗失败率C-CXL组为23.1%(9/39眼) vs A-CXL组为15.4%(6/39眼),P=0.389。
  • 不良事件仅C-CXL组1眼出现,表现为BCVA较基线下降≥2行Snellen视力。

关键数值与推荐

  • 入选标准为地形图确诊的进展性圆锥角膜且手术时角膜厚度≥400 μm。
  • 治疗失败定义为随访期间Kmax增加超过1.0 D的眼数百分比。
  • 不良事件定义为BCVA较基线下降≥2行Snellen视力的眼数百分比。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare visual and topographic outcomes 1 year after conventional (C-CXL) vs accelerated corneal cross-linking (A-CXL) in pediatric keratoconus (KC). DESIGN: Comparative, retrospective, consecutive case series. METHODS: Patients with topography-confirmed, progressive KC and a corneal thickness of ≥400 μm at the time of surgery were enrolled. Uncorrected (UCVA) and best phoropter-corrected visual acuity (BCVA) and normal maximum keratometry reading (Kmax) were measured at study entry and at the 12-month follow-up. Treatment failure rate was defined as the percentage of eyes with an increase in Kmax of more than 1.0 diopter during follow-up. The adverse event rate was the percentage of eyes with a loss of ≥2 Snellen lines of BCVA from baseline. This was a single-center analysis of 78 eyes of 58 patients that underwent C-CXL (39 eyes) and A-CXL (39 eyes). No eyes were lost to follow-up after 12 months. RESULTS: No significant difference between changes in 12 months after as compared to the time before CXL for UCVA (0.01 log MAR; 95% confidence interval -0.14 to 0.15, P = .944), BCVA (0.05 log MAR; 95% confidence interval -0.05 to 0.15, P = .310), and Kmax (-0.77 diopters; 95% confidence interval -2.20 to 0.65, P = .282) between the C-CXL and A-CXL group were observed. Treatment failure rate was observed in 9 of 39 eyes (23.1%) in C-CXL and in 6 of 39 eyes (15.4%) in A-CXL (P = .389). Adverse events were seen only in 1 eye in the C-CXL group. CONCLUSIONS: In this retrospective comparison, the accelerated approach was equally as effective as the conventional protocol to treat pediatric keratoconus.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Baenninger PB, Bachmann LM, Wienecke L, et al. Pediatric Corneal Cross-linking: Comparison of Visual and Topographic Outcomes Between Conventional and Accelerated Treatment. Am J Ophthalmol. 2017. PMID: 28864070. doi:10.1016/j.ajo.2017.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。